Visual hallucinations in Parkinson´s disease and amyloid burden: 18F-Flutemetamol PET-MRI study
Objective: To compare amyloid distribution in patients with Parkinson´s disease (PD) with visual hallucinations (VH-p) and without (VH-n). Background: In patients with PD the prevalence…Impaired colour discrimination is associated with hallucinations in Dementia with Lewy Bodies
Objective: To explore the hypothesis that color discrimination impairment seen in Lewy body disorders is a specific biomarker of visual hallucinations rather than just overall…Visual hallucinations in Lewy Body Disease are characterised by impaired sensory integration
Objective: To test whether increased reliance on prior knowledge is associated with visual hallucinations in Lewy Body Disease (LBD: Parkinson’s disease and Dementia with Lewy…Daily variability of non-motor symptoms as a reflection of circadian dysregulation in Parkinson’s disease
Objective: To assess the daily variability of visual and autonomic nervous system (ANS) functions in relation to sleep disorders to determine circadian PD phenotypes Background:…Olfactory Hallucinations as a Non-motor sign of Parkinson’s disease- a cross sectional study
Objective: To describe the prevalence and characteristics of Olfactory Hallucinations (OlfH) in patients with Parkinson’s Disease (PD) in a tertiary movement clinic. Background: Hallucinations are…Relationship between RBD and olfactory disorder, clinical symptoms in Parkinson’s disease
Objective: We aimed to assess the association among RBD, olfactory function and clinical symptoms in patients with Parkinson's disease (PD). Background: Rapid eye movement sleep…Visual subnetwork dysfunction in Parkinson’s patients with primary visual hallucinations
Objective: To evaluate impairments in the visual subnetwork in Parkinson’s disease (PD) patients with psychosis using BOLD fMRI Background: Psychosis occurs in 20-70% of patients…Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease
Objective: In the treatment of Parkinson’s disease, dopamine agonists are among the preferred treatment options, particularly in the treatment of young Parkinson’s patients. The known…Lewy body disease with visual hallucination: Optic radiation abnormalities on phase difference-enhanced imaging (PADRE)
Objective: We assessed structural abnormalities of optic radiation (OR) in healthy subjects (HS) and dementia with lewy body (DLB) patients (with visual hallucination) (VH) on…Early cortical signature of development of visual hallucinations in ‘de novo’ Parkinson’s disease
Objective: To explore, in patients with newly diagnosed Parkinson's disease (PD), grey matter volume (GMV) differences at baseline in those participants who will develop hallucinations…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 10
- Next Page »